Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0MI81)

• Drug Name: Bevacizumab + Erlotinib Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Metastatic colorectal cancer	2B91	Phase 3	[1] , [2]
Non-small-cell lung cancer	2C25.Y	Phase 3	[1] , [2]
Hepatocellular carcinoma	2C12.02	Phase 2	[3] , [4] , [5] , [6] , [7] , [8]
Hypopharyngeal squamous cell carcinoma	2B6D.0	Phase 1/2	[9]

• Cross-matching ID: TTD Drug ID: DM0MI81

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor A (VEGFA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aflibercept	DMT3D5I	Metastatic colorectal cancer	2B91	Approved	[11]
Brolucizumab	DMW8QNG	Wet age-related macular degeneration	9B78.3Z	Approved	[12]
Ranibizumab	DMSYPNW	Hereditary hemorrhagic telangiectasia	LA90.00	Approved	[13]
Bevacizumab	DMSD1UN	Metastatic colorectal cancer	2B91	Approved	[14]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[15]
Bevacizumab + Trastuzumab	DM9CEI5	Breast cancer	2C60-2C65	Phase 3	[10]
Bevacizumab + Rituximab	DM9EXGI	Lymphoma	2A80-2A86	Phase 3	[10]
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Phase 3	[16]
PTC299	DMP9TKE	Rheumatoid arthritis	FA20	Phase 2	[17]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[18]

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[19]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[20]
Gefitinib	DM15F0X	Solid tumour/cancer	2A00-2F9Z	Approved	[21]
Erlotinib	DMCMBHA	Non-small-cell lung cancer	2C25.Y	Approved	[22]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[23]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[24]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[25]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[26]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[24]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[27]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[10]
Vascular endothelial growth factor A (VEGFA)	TTOHSBA	VEGFA_HUMAN	Inhibitor	[10]

References

• [1] ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
• [2] ClinicalTrials.gov (NCT00598156) Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva
• [3] ClinicalTrials.gov (NCT01130519) A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT00287222) Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
• [5] ClinicalTrials.gov (NCT02655536) Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial
• [6] Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S17-23.
• [7] Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011 May 28;377(9780):1846-54.
• [8] ClinicalTrials.gov (NCT00365391) Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
• [9] ClinicalTrials.gov (NCT00055913) Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
• [10] Clinical pipeline report, company report or official report of Roche (2009).
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [13] Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70.
• [14] FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
• [15] Clinical pipeline report, company report or official report of Genentech (2009).
• [16] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [17] Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24.
• [18] Bispecific antibodies and their applications
• [19] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [20] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [21] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [22] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [23] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [25] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [26] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [27] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).